BOOK
Castleman Disease, An Issue of Hematology/Oncology Clinics, E-Book
Frits van Rhee | Nikhil C. Munshi
(2017)
Additional Information
Book Details
Abstract
This issue of Hematology/Oncology Clinics, edited by Dr. Frits van Rhee and Dr. Nikhil C. Munshi, focuses on Castleman Disease. Topics include, but are not limited to, Epidemiology; Pathogenesis; Role of Interleukin 6 in Castleman Disease; Pathology, Diagnosis; Unicentric Castleman Disease; Treatment of HHV8 related Multicentric Castleman Disease; Treatment of HHV8 negative Castleman Disease; TAFRO Syndrome; POEMS; and more.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Castleman Disease\r | i | ||
| Copyright\r | ii | ||
| Contributors | iii | ||
| CONSULTING EDITORS | iii | ||
| EDITORS | iii | ||
| AUTHORS | iii | ||
| Contents | vii | ||
| Preface: Castleman Disease | vii | ||
| Epidemiology of Castleman Disease | vii | ||
| Castleman Disease Pathogenesis | vii | ||
| The Role of Interleukin-6 in Castleman Disease | vii | ||
| Pathology of Castleman Disease | viii | ||
| Diagnosis of Castleman Disease | viii | ||
| Unicentric Castleman Disease | viii | ||
| Treatment of Kaposi Sarcoma Herpesvirus–Associated Multicentric Castleman Disease | viii | ||
| Treatment of Idiopathic Castleman Disease | ix | ||
| TAFRO Syndrome | ix | ||
| POEMS Syndrome: Diagnosis and Investigative Work-up | ix | ||
| POEMS Syndrome: Therapeutic Options | ix | ||
| The Peripheral Neuropathies of POEMS Syndrome and Castleman Disease | x | ||
| HEMATOLOGY/ONCOLOGY\rCLINICS OF NORTH AMERICA\r | xi | ||
| FORTHCOMING ISSUES | xi | ||
| April 2018 | xi | ||
| June 2018 | xi | ||
| August 2018 | xi | ||
| RECENT ISSUES | xi | ||
| December 2017 | xi | ||
| October 2017 | xi | ||
| August 2017 | xi | ||
| Preface:\rCastleman Disease | xiii | ||
| REFERENCE | xiv | ||
| Epidemiology of Castleman Disease | 1 | ||
| Key points | 1 | ||
| UNICENTRIC CASTLEMAN DISEASE | 2 | ||
| HUMAN HERPESVIRUS-8 PLUS MULTICENTRIC CASTLEMAN DISEASE | 4 | ||
| IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE | 5 | ||
| POLYNESIAN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE | 5 | ||
| POLYRADICULONEUROPATHY, ORGANOMEGALY, ENDOCRINOPATHY, MONOCLONAL PLASMA CELL NEOPLASM, AND SKIN CHANGES RELATED TO IDIOPATH ... | 6 | ||
| THROMBOCYTOPENIA, ANASARCA, FEVER, RENAL INSUFFICIENCY, AND ORGANOMEGALY | 7 | ||
| SUMMARY | 7 | ||
| REFERENCES | 8 | ||
| Castleman Disease Pathogenesis | 11 | ||
| Key points | 11 | ||
| INTRODUCTION | 11 | ||
| UNICENTRIC CASTLEMAN DISEASE | 13 | ||
| Cause | 13 | ||
| Cell Type | 13 | ||
| Signaling Pathways | 13 | ||
| Effector Cytokines | 14 | ||
| HUMAN HERPESVIRUS-8–ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE | 14 | ||
| Cause | 14 | ||
| Cell Type | 14 | ||
| Signaling Pathways | 14 | ||
| Effector Cytokines | 15 | ||
| HUMAN HERPESVIRUS-8–NEGATIVE MULTICENTRIC CASTLEMAN DISEASE | 15 | ||
| POEMS–Associated Multicentric Castleman Disease | 15 | ||
| Cause/cell type | 15 | ||
| Signaling pathways/effector cytokines | 15 | ||
| Idiopathic Multicentric Castleman Disease | 15 | ||
| Cause | 15 | ||
| Autoimmune | 15 | ||
| Autoinflammatory | 16 | ||
| Neoplastic | 16 | ||
| Pathogen | 16 | ||
| Cell type | 17 | ||
| Signaling pathways/effector cytokines | 17 | ||
| FUTURE DIRECTIONS | 18 | ||
| REFERENCES | 18 | ||
| The Role of Interleukin-6 in Castleman Disease | 23 | ||
| Key points | 23 | ||
| INTRODUCTION | 23 | ||
| DISCOVERY, PRODUCTION, AND FUNCTION OF INTERLEUKIN-6 | 24 | ||
| INTERLEUKIN-6 RECEPTOR SYSTEM AND SIGNAL TRANSDUCTION PATHWAY | 25 | ||
| REVELATION OF THE ROLE OF INTERLEUKIN-6 IN THE PATHOGENESIS OF CASTLEMAN DISEASE | 25 | ||
| BLOCKING INTERLEUKIN-6 FUNCTION WITH A HUMANIZED ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY | 28 | ||
| CLINICAL USE OF A HUMANIZED ANTI-INTERLEUKIN-6R ANTIBODY | 29 | ||
| CLINICAL STUDY OF TOCILIZUMAB OR SILTUXIMAB FOR MULTICENTRIC CASTLEMAN DISEASE THERAPY | 30 | ||
| SUMMARY | 33 | ||
| ACKNOWLEDGMENTS | 35 | ||
| REFERENCES | 35 | ||
| Pathology of Castleman Disease | 37 | ||
| Key points | 37 | ||
| INTRODUCTION | 37 | ||
| HISTOPATHOLOGIC FEATURES | 41 | ||
| Unicentric Castleman Disease | 41 | ||
| Multicentric Castleman Disease | 43 | ||
| Hypervascular variant of multicentric disease | 43 | ||
| Plasmacytic variant of multicentric disease | 44 | ||
| Thrombocytopenia, ascites/anasarca, myelofibrosis/fever, renal dysfunction/reticulin fibrosis, and organomegaly syndrome | 45 | ||
| Human Herpes Virus 8-Positive, Castleman Disease | 45 | ||
| HISTOLOGIC DIFFERENTIAL DIAGNOSES | 46 | ||
| CONSENSUS DIAGNOSTIC CRITERIA FOR HUMAN HERPES VIRUS 8-NEGATIVE, IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE | 47 | ||
| SUMMARY AND DISCUSSION | 48 | ||
| REFERENCES | 49 | ||
| Diagnosis of Castleman Disease | 53 | ||
| Key points | 53 | ||
| PRESENTATION | 54 | ||
| HISTOPATHOLOGICAL EXAMINATION OF CASTLEMAN DISEASE | 54 | ||
| LABORATORY AND RADIOLOGICAL INVESTIGATIONS | 55 | ||
| UNICENTRIC CASTLEMAN DISEASE | 55 | ||
| HUMAN HERPESVIRUS 8 AND HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE MULTICENTRIC CASTLEMAN DISEASE | 57 | ||
| MULTICENTRIC CASTLEMAN DISEASE HUMAN HERPESVIRUS 8-POSITIVE HUMAN IMMUNODEFICIENCY VIRUS-NEGATIVE | 57 | ||
| IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE | 57 | ||
| SPECIFIC PRESENTATIONS OF CASTLEMAN DISEASE | 59 | ||
| Paraneoplastic Pemphigus | 59 | ||
| POEMS | 59 | ||
| TAFRO | 61 | ||
| HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS | 61 | ||
| AUTOIMMUNE CYTOPENIA | 61 | ||
| PERIPHERAL NEUROPATHY | 61 | ||
| RENAL INVOLVEMENT | 62 | ||
| DIFFERENTIAL DIAGNOSIS | 62 | ||
| REFERENCES | 62 | ||
| Unicentric Castleman Disease | 65 | ||
| Key points | 65 | ||
| INTRODUCTION | 65 | ||
| CLINICAL MANIFESTATIONS | 66 | ||
| INVESTIGATIONS AND DIAGNOSIS | 66 | ||
| Plain Radiographs | 66 | ||
| Computed Tomography | 66 | ||
| MRI | 67 | ||
| Ultrasonography | 67 | ||
| PET | 67 | ||
| Laboratory Studies | 68 | ||
| TREATMENT | 68 | ||
| Surgery | 68 | ||
| Radiotherapy | 68 | ||
| Other Therapeutic Options | 68 | ||
| PROGNOSIS | 69 | ||
| DISEASES ASSOCIATED WITH UNICENTRIC CASTLEMAN DISEASE | 69 | ||
| Paraneoplastic Pemphigus | 69 | ||
| Lymphoma | 69 | ||
| Follicular Dendritic Cell Sarcoma | 69 | ||
| SUMMARY | 69 | ||
| REFERENCES | 70 | ||
| Treatment of Kaposi Sarcoma Herpesvirus–Associated Multicentric Castleman Disease | 75 | ||
| Key points | 75 | ||
| INTRODUCTION | 75 | ||
| EPIDEMIOLOGY | 76 | ||
| PATHOGENESIS | 76 | ||
| DIAGNOSIS | 77 | ||
| TREATMENT | 79 | ||
| SUMMARY | 84 | ||
| DISCLOSURES | 84 | ||
| ACKNOWLEDGMENTS | 85 | ||
| REFERENCES | 85 | ||
| Treatment of Idiopathic Castleman Disease | 89 | ||
| Key points | 89 | ||
| INTRODUCTION | 89 | ||
| CLINICAL SYMPTOMATOLOGY OF MULTICENTRIC CASTLEMAN DISEASE AND ROLE OF INTERLEUKIN-6 | 90 | ||
| Multicentric Castleman Disease Classification and Therapy | 91 | ||
| Therapeutic Options for Idiopathic Multicentric Castleman Disease | 92 | ||
| Overview | 92 | ||
| Overall outcome of idiopathic multicentric Castleman disease | 92 | ||
| Surgery and irradiation | 93 | ||
| Corticosteroids | 93 | ||
| Chemotherapy | 93 | ||
| Rituximab | 94 | ||
| Anti-IL6 agents | 94 | ||
| Immunomodulatory agents | 97 | ||
| Treatment Guidelines and Algorithm | 98 | ||
| SUMMARY | 100 | ||
| REFERENCES | 100 | ||
| TAFRO Syndrome | 107 | ||
| Key points | 107 | ||
| INTRODUCTION | 107 | ||
| CLINICAL CHARACTERISTICS | 109 | ||
| Age at Onset | 109 | ||
| Symptoms | 109 | ||
| Laboratory Findings | 109 | ||
| HISTOPATHOLOGICAL CHARACTERISTICS | 110 | ||
| Lymph Nodes | 110 | ||
| Bone Marrow | 110 | ||
| DIAGNOSIS | 110 | ||
| The Need for Differential Diagnosis | 110 | ||
| Proposed Diagnostic Criteria | 111 | ||
| Importance of Lymph Node Biopsy | 113 | ||
| PROGNOSIS AND CLASSIFICATION OF SEVERITY | 113 | ||
| DISEASE MECHANISMS | 114 | ||
| The Role of Interleukin-6 | 114 | ||
| Platelet Count Depletion | 114 | ||
| Is Bacterial Infection a Cause of TAFRO Syndrome? | 114 | ||
| CLINICAL MANAGEMENT | 115 | ||
| SUMMARY | 115 | ||
| REFERENCES | 116 | ||
| POEMS Syndrome | 119 | ||
| Key points | 119 | ||
| INTRODUCTION | 119 | ||
| HISTORY | 120 | ||
| PATHOPHYSIOLOGY | 121 | ||
| PERIPHERAL NEUROPATHY | 121 | ||
| MONOCLONAL PLASMA CELL DISORDER AND HEMATOLOGIC FINDINGS | 123 | ||
| BONE LESIONS | 124 | ||
| EXTRAVASCULAR VOLUME OVERLOAD | 124 | ||
| VASCULAR ENDOTHELIAL GROWTH FACTOR AND OTHER CYTOKINES | 125 | ||
| ORGANOMEGALY | 125 | ||
| ENDOCRINOPATHY | 125 | ||
| SKIN FINDINGS | 125 | ||
| PAPILLEDEMA | 126 | ||
| RESPIRATORY FINDINGS | 126 | ||
| RENAL FINDINGS | 126 | ||
| THROMBOSIS | 127 | ||
| OTHER LABORATORY FINDINGS | 128 | ||
| DIFFERENTIAL DIAGNOSIS | 128 | ||
| TESTING GUIDELINES | 130 | ||
| SUMMARY POINTS | 130 | ||
| REFERENCES | 130 | ||
| POEMS Syndrome | 141 | ||
| Key points | 141 | ||
| INTRODUCTION | 141 | ||
| UNDERLYING HEMOPATHY | 142 | ||
| SPECIFIC TREATMENTS | 142 | ||
| TREATMENT WHEN THERE ARE 1 TO 3 BONE LESIONS AND NO DISSEMINATED BONE MARROW INVOLVEMENT | 143 | ||
| TREATMENT WHEN THERE IS DISSEMINATED BONE MARROW INVOLVEMENT OR NO BONE LESION OR MANY BONE LESIONS | 144 | ||
| SECOND-LINE TREATMENT | 147 | ||
| MONITORING RESPONSE | 148 | ||
| PROGNOSIS | 148 | ||
| SUPPORTING TREATMENT | 149 | ||
| CONCLUDING REMARKS | 149 | ||
| REFERENCES | 149 | ||
| The Peripheral Neuropathies of POEMS Syndrome and Castleman Disease | 153 | ||
| Key points | 153 | ||
| INTRODUCTION | 153 | ||
| POLYNEUROPATHY, ORGANOMEGALY, ENDOCRINOPATHY, MONOCLONAL PLASMA CELL-PROLIFERATIVE DISORDER, SKIN CHANGES (POEMS) SYNDROME | 154 | ||
| General | 154 | ||
| Neuropathy Characteristics | 155 | ||
| Evaluation | 155 | ||
| Electrodiagnostic Characteristics | 156 | ||
| Radiologic Features | 156 | ||
| Pathologic Features | 157 | ||
| Treatment | 157 | ||
| CASTLEMAN DISEASE | 159 | ||
| General | 159 | ||
| Neuropathy Characteristics | 160 | ||
| Evaluation | 160 | ||
| Electrophysiologic Features | 160 | ||
| Pathologic Features | 161 | ||
| Treatment | 161 | ||
| SUMMARY | 161 | ||
| REFERENCES | 161 |